Stockscreener 앱 받기
48.10
1.84%
-0.90
시장 영업 전:
48.55
0.45
+0.94%
전일 마감가:
$49.00
열려 있는:
$49
하루 거래량:
269.09K
Relative Volume:
0.72
시가총액:
$3.43B
수익:
$751.00K
순이익/손실:
$-74.57M
주가수익비율:
-43.60
EPS:
-1.1031
순현금흐름:
$-55.52M
1주 성능:
+2.30%
1개월 성능:
+59.11%
6개월 성능:
+149.35%
1년 성능:
+184.45%
1일 변동 폭
$47.92
$49.74
1주일 범위
$46.34
$50.90
52주 변동 폭
$12.56
$50.90
펄스 바이오 Stock (PLSE) Company Profile
명칭
Pulse Biosciences Inc
전화
510-906-4600
주소
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, RMD, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
48.10 | 3.41B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
370.42 | 132.30B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
190.21 | 51.11B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
72.67 | 35.25B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
235.69 | 32.95B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
34.58 | 28.58B | 29.14B | 1.07B | 1.05B | 1.1956 |
펄스 바이오 Stock (PLSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 개시 | Mizuho | Outperform |
| 2025-07-07 | 개시 | Oppenheimer | Outperform |
| 2021-07-27 | 개시 | Stephens | Overweight |
| 2021-03-11 | 개시 | Maxim Group | Buy |
| 2021-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-12 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 개시 | H.C. Wainwright | Buy |
모두보기
펄스 바이오 주식(PLSE)의 최신 뉴스
Total assets of Pulse Biosciences, Inc. – HAM:6L8 - TradingView
Operating cash flow per share of Pulse Biosciences, Inc. – HAM:6L8 - TradingView
Pulse Biosciences stock hits all-time high at 48.92 USD - Investing.com
$Pulse Biosciences (PLSE.US)$ shorties getting squeezed - Moomoo
Pulse (PLSE) Results Review: EPS Clears the Reported Estimate; Trading Move: Shares Rise 2.22% in the Latest ReadingDividend Growth Analysis - Vinanet
Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE - MarketBeat
Pulse Biosciences (PLSE) Launched A $75 Million Offering, Is The Upside Already Priced In? - Sahm
Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year HighHere's Why - MarketBeat
Pulse (PLSE) Earnings Review: EPS Exceeds Its Estimate in the Current Update; Reaction Snapshot - vinanet.vn
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 18, 2026 - BioSpace
Pulse Biosciences (PLSE) Grants Equity Awards to New Hires Amid High Price-to-Sales Valuation - GuruFocus
This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
This Okta Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
Pulse Biosciences, Inc (NASDAQ:PLSE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Needham & Company LLC Initiates Coverage on Pulse Biosciences (NASDAQ:PLSE) - MarketBeat
PLSE Initiates Coverage On by Needham -- Price Target Announced at $58.00 - GuruFocus
Needham initiates Pulse Biosciences stock with buy on ablation tech By Investing.com - Investing.com Canada
Needham Initiates Pulse Biosciences at Buy With $58 Price Target - marketscreener.com
PULSE BIOSCIENCES INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $58 - Bitget
Pulse Biosciences (PLSE) Is Up 5.0% After Wider Losses And $75M ATM Plan Filed – Has The Bull Case Changed? - simplywall.st
Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns - Yahoo Finance
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform - marketbeat.com
(PLSE) Risk Channels and Responsive Allocation - Stock Traders Daily
Pulse Biosciences (PLSE) Prices A $75 Million Offering, Is The Stock Fully Valued? - Yahoo Finance
PLSE Virtual Meeting on Strategic Initiatives Highlights Growth Expectations Despite High Valuation - GuruFocus
Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript - AOL.ca
Pulse Biosciences stock reaches all-time high at 46.03 USD By Investing.com - Investing.com Australia
Pulse Biosciences stock reaches all-time high at 46.03 USD - Investing.com
$Pulse Biosciences (PLSE.US)$ SQUEEZING THE SHORTIES - Moomoo
Pulse Biosciences at Canaccord Genuity conference: nsPFA push gains pace By Investing.com - Investing.com Canada
PLSE: nsPFA technology delivers breakthrough efficacy in AFib and is poised for broad clinical adoption - TradingView
Pulse Biosciences, Inc. (PLSE) Stock Analysis: Exploring the Innovative Potential of a $2.96 Billion Bioelectric Medicine Leader - DirectorsTalk Interviews
PLSE to Join BTIG Virtual Meeting Amid Elevated Price-to-Sales V - GuruFocus
PLSE Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus
Canaccord Genuity Group Issues Positive Forecast for Pulse Biosciences (NASDAQ:PLSE) Stock Price - MarketBeat
Canaccord raises Pulse Biosciences stock price target on clinical progress - Investing.com India
Canaccord raises Pulse Biosciences stock price target on clinical progress By Investing.com - Investing.com Canada
Weekly Recap: Q2 losses, ATM raises and NANOPULSE-AF study past halfway - TradingView
Pulse Biosciences (NASDAQ:PLSE) Announces Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Pulse Biosciences, Inc. (PLSE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pulse Biosciences (NASDAQ:PLSE) Stock Rating Lowered by Wall Street Zen - MarketBeat
Q2 2026 Pulse Biosciences Inc Earnings Call Transcript - GuruFocus
Pulse Biosciences, Inc. (PLSE) stock price, news, quote and history - uk.finance.yahoo.com
Sector Update: Healthcare - Moomoo
Pulse Biosciences Shares Rise After Q2 Results - marketscreener.com
Pulse Biosciences (NASDAQ:PLSE) Trading Up 15.7%Should You Buy? - MarketBeat
Pulse Biosciences enters $75 million equity distribution agreement with Mizuho - Investing.com Australia
Pulse Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pulse Biosciences (PLSE) Accelerates Clinical Enrollment, Market Pricing Reflects High Growth Expectations - GuruFocus
Earnings call transcript: Pulse Biosciences misses Q2 2026 estimates but gains on trial progress - Investing.com Canada
Form 8K Pulse Biosciences Inc For: 6 August By Investing.com - Investing.com Nigeria
펄스 바이오 (PLSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
펄스 바이오 주식 (PLSE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
0.29%
0.80%
자본화:
|
볼륨(24시간):